Mild Improvement in Mitochondrial Function After a 3-Year Antiretroviral Treatment Interruption Despite Persistent Impairment of Mitochondrial DNA Content

Author(s): Eugenia Negredo, Joan Romeu, Benjami Rodriguez-Santiago, Oscar Miro, Gloria Garrabou, Jordi Puig, Nuria Perez-Alvarez, Constanza Moren, Lidia Ruiz, Rocio Bellido, Cristina Miranda, Bonaventura Clotet.

Journal Name: Current HIV Research

Volume 8 , Issue 5 , 2010

Become EABM
Become Reviewer

Abstract:

Objective: The ability of a prolonged antiretroviral treatment interruption to reverse mitochondrial toxicity was evaluated in a sub-study of TIBET, a prospective trial examining antiretroviral treatment interruption guided by CD4+ cell count. Patients and Methods: The study population was composed of patients from the TIBET study who had been followed for ≥96 weeks and whose peripheral blood mononuclear cells (PBMCs) had been collected at baseline and throughout the study period. Of the 201 patients included in the TIBET study, 38 were selected for the mitochondrial sub-study; 18 patients discontinued antiretroviral therapy for ≥96 weeks and 20 maintained therapy. Mitochondrial DNA (mtDNA) and RNA (mtRNA) were measured in PBMCs using real-time polymerase chain reaction, and mitochondrial function relative to mitochondrial content was assessed using the cytochrome c oxidase and citrate synthase ratio (COX/CS). Results: Whereas mtDNA content showed a similar progressive decrease throughout the study period in both arms, the mtRNA amount remained stable in both groups and the COX/CS ratio improved significantly in patients who interrupted therapy. Conclusions: Mitochondrial function improved during a prolonged antiretroviral treatment interruption despite a decrease in mtDNA levels in PBMCs, probably because of the existence of a mitochondrial transcriptional and translational upregulation mechanism or the reversion of mitochondrial toxicity by a mechanism that is independent of DNA polymerase gamma. The reduction in virus-related mitochondrial damage should be considered another relevant benefit of antiretroviral therapy.

Keywords: Antiretroviral treatment interruption, mitochondrial toxicity, mitochondrial DNA, COX activity, HIV-infection, comparative-controlled trial

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 8
ISSUE: 5
Year: 2010
Page: [379 - 385]
Pages: 7
DOI: 10.2174/157016210791330374
Price: $65

Article Metrics

PDF: 2